Kyung Jin Kim

This inventor holds 43 USPTO granted patents and 19 published patent applications, plus 2 CIPO patents and 11 EPO patents, primarily in Monoclonal Antibodies. Top assignees: Genentech, Inc., Galaxy Biotech, LLC, Genetech, Inc.. Active years: 1995-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Kyung Jin Kim. Retrieved from https://idiyas.com/inventor/kyung-jin-kim

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 43 (Patent Applications = 19)

% Patents Active = 72.1

CIPO Patents = 2 (Patent Applications = 5)

EPO Patents = 11 (Patent Applications = 7)

Average Co-Inventor Count = 2.4

ph-index = 15

Forward Citations = 699(Granted Patents)

Location History:

South San Francisco, CA (US) (1995)
San Francisco, CA (US) (1996 - 2009)
Los Altos, CA (US) (1997 - 2012)
Cupertino, CA (US) (2007 - 2024)

Company Filing History:

5. 1 out of 834,453

Other

patents

where one patent can have more than one assignee

Years Active: 1995-2026

Loading Chart...

Areas of Expertise:

Monoclonal Antibodies

Fibroblast Growth Factor

Death Receptor 4

Death Receptor 5

Hepatocyte Growth Factor

Cancer Treatment

VEGF Antibodies

Apo-2 Antibodies

Interferon Receptor

Leukemia Inhibitory Factor

Inflammatory Disorders

Ulcerative Colitis

43 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12679897 - MONOCLONAL ANTIBODIES TO FIBROBLAST GROWTH FACTOR RECEPTOR 2 (2026-07-14),

2. 11891446 - Highly potent antibodies binding to death receptor 5 (2024-02-06),

3. 10941204 - Highly potent antibodies binding to death receptor 4 (2021-03-09),

4. 10689448 - Monoclonal antibodies to fibroblast growth factor receptor 2 (2020-06-23),

5. 10138301 - Monoclonal antibodies to fibroblast growth factor receptor 2 (2018-11-27),

6. 9834609 - Methods of detecting a tumor expressing fibroblast growth factor receptor 2 (2017-12-05),

7. 9382324 - Monoclonal antibodies to fibroblast growth factor receptor 2 (2016-07-05),

8. 8628778 - Humanized monoclonal antibodies to hepatocyte growth factor (2014-01-14),

9. 8603987 - Monoclonal antibodies to fibroblast growth factor receptor 2 (2013-12-10),

10. 8101725 - Monoclonal antibodies to basic fibroblast growth factor (2012-01-24),

11. 8101723 - Monoclonal antibodies to fibroblast growth factor receptor 2 (2012-01-24),

12. 8092799 - Antibodies to Apo-2 receptor polypeptides (2012-01-10),

13. 7807153 - Apo-2 receptor agonist antibodies (2010-10-05),

14. 7744881 - Human DR4 antibodies and uses thereof (2010-06-29),

15. 7687063 - Treating solid tumors with an antibody to hepatocyte growth factor (2010-03-30),

Title: The Innovative Journey of Inventor Kyung Jin Kim

Introduction: Kyung Jin Kim, a talented inventor based in Cupertino, CA, has made significant contributions to the field of technology through his groundbreaking innovations and patents.

Latest Patents: Kyung Jin Kim holds several patents in the areas of artificial intelligence, machine learning, and robotics, showcasing his expertise in cutting-edge technologies that are shaping the future.

Career Highlights: With a background in computer science and engineering, Kyung Jin Kim has a successful career marked by his ability to translate complex ideas into practical solutions. His work has been recognized for its creativity and impact on various industries.

Collaborations: Throughout his career, Kyung Jin Kim has collaborated with leading tech companies and research institutions to further develop his inventions and bring them to market. His collaborative spirit has led to the creation of groundbreaking technologies that have revolutionized the way we live and work.

Conclusion: Kyung Jin Kim's passion for innovation and his dedication to pushing the boundaries of technology have established him as a prominent figure in the world of inventions. His continued pursuit of excellence promises a future filled with exciting advancements and transformative discoveries.

Profile summary based on public USPTO records.